BIND Therapeutics, Inc. (NASDAQ: BIND) disclosed that it opted to file for a voluntary petition under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court for the District of Delaware in the ...
Financially pressed Bind Therapeutics Inc. said Monday it has filed for federal bankruptcy protection after the breakdown of talks to restructure its debt, a rare misstep for one of the many Cambridge ...
BIND has requested the U.S. Bankruptcy Court to authorize the Company to proceed with an auction on July 25, 2016 for the majority of its assets, provided the Company receives qualified overbids no ...
Cambridge, MA, August 12, 2013 — BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that it has filed ...
Cambridge biotechnology company Bind Therapeutics Inc., which is developing a class of programmable drugs to fight lung cancer, prostate cancer, and other diseases, registered Monday for an initial ...
Bind Therapeutics, an oncology nanomedicine drug discovery company, and its affiliate Bind Biosciences Security Corp., have filed a reorganization petition in the U.S. Bankruptcy Court for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback